Callitas Health Overview

  • Founded

  • 2013

Founded
  • Status

  • Public

  • Investments

  • 8

  • Share Price

  • $0.01

  • (As of Friday Closing)

Callitas Health General Information

Description

Callitas Health Inc is a clinical-stage company. It is engaged in developing technologies for the monitoring and treatment of obesity, diabetes, and other gastroenterological indications. The company's products offering includes ToConceive, C-103 Reformulated Orlistat, and Extrinsa. ToConceive is a fertility enhancing moisturizer. It is clinically proven to increase a woman's own natural conception lubrication, called transudate, to aid in conception. Orlistat is FDA-approved for weight management and sold by Roche as Xenical (prescription) and by GlaxoSmithKline as alli. Extrinsa focuses on women with orgasm and arousal difficulties. The topical, local, and the non-systemic product is also non-hormonal and does not affect the central nervous system.

Contact Information

Website
www.callitas.com
Formerly Known As
M Pharmaceutical Inc., Callitas Therapeutics
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Former Stock Listing
MPHMF
Primary Office
  • 187 Pavilion Parkway
  • Suite 200
  • Newport, KY 41071
  • United States
+1 (859) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Callitas Health Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.01 $0.02 45.3M 9.5K -$0.01

Callitas Health Financials Summary

In Thousands,
USD 		TTM 30-Sep-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018 FY 2017 31-Dec-2017
EV 3,397 6,722
Revenue 506 534 579 495
EBITDA (396) (1,205) (3,749) (5,856)
Net Income (522) (1,280) (4,222) (6,608)
Total Assets 101 142 17 3,624
Total Debt 827 660 235 205
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Callitas Health Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Callitas Health‘s full profile, request access.

Request a free trial

Callitas Health Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Callitas Health Inc is a clinical-stage company. It is engaged in developing technologies for the monitoring and treatme
Biotechnology
Newport, KY
00000
000000000 00000

000000

t, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et do
0000 000000000
Boston, MA
00 As of 0000
00000
000000000 00000

000000

elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim
0000 000000000
South San Francisco, CA
00 As of 0000
00000
0000 0000-00-00
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Callitas Health Competitors (11)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Gelesis Formerly VC-backed Boston, MA 00 00000 000000000 00000
00000000 Venture Capital-Backed South San Francisco, CA 00 00000 00000000000 00000
00000 000000000000 Venture Capital-Backed Cambridge, MA 00 00000 00000000000 00000
00000 Corporate Backed or Acquired Campbell, CA 00 00000 000000&0
000000000 Formerly VC-backed San Ramon, CA 00 00000 000000&0
You’re viewing 5 of 11 competitors. Get the full list »

Callitas Health Patents

  • 2

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 1

    Granted

  • 1

    Pending

  • 000

    Expiring in next 12 mo

Callitas Health Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20220331292-A1 Compositions and methods for delivery of psilocin and prodrugs thereof Pending 16-Apr-2021 00000000000 0
US-10383819-B1 Method to effect biphasic bioavailability of oral euphoric psychogenic cannabinoids Active 23-Jul-2018 0000000000

Callitas Health Executive Team (11)

Name Title Board Seat Contact Info
James Thompson Chief Executive Officer & President
Brain Keane JD Chief Executive Officer & Director
Laura Berman Chief Health Advisor
Joshua Maurice Vice President of Sales and Business Development
You’re viewing 4 of 11 executive team members. Get the full list »

Callitas Health Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Callitas Health‘s full profile, request access.

Request a free trial

Callitas Health Investments & Acquisitions (8)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000 0000000 02-Oct-2018 000000000 Buildings and Property 00000 000
00 0'0 12-Jan-2017 0000000000 00.00 Drug Discovery 0000 0000
0000000000 08-Nov-2016 0000000000 00000 Pharmaceuticals 00000 000
000000000 (00 15-Jul-2016 0000000000 00000 Pharmaceuticals 000000 00
Trimtec Biomedical 26-Jun-2015 Merger/Acquisition Biotechnology
You’re viewing 5 of 8 investments and acquisitions. Get the full list »

Ready to get started?

Request a free trial